New Executive Interview: Salipro Biotech & Bio-Rad Featured in Drug Development & Delivery
Out now - an executive interview with Francisco Ylera from Bio-Rad Laboratories and Jens Frauenfeld from Salipro Biotech published in Drug Development & Delivery features a straightforward solution for tackling one of biotech's toughest challenges: discovering therapeutic antibodies against complex transmembrane proteins.
In a short timeframe, the collaboration has already yielded exciting results: novel human antibodies targeting the challenging chemokine receptor, CXCR4. These antibodies demonstrate:
Higher affinity than the current benchmark antibody ulocuplumab
Enhanced functionality in cell-based assays
Potential new mechanisms of action for CXCR4-mediated therapeutics
This success is enabled by combining the Salipro® platform for stabilizing native membrane proteins with Bio-Rad's Pioneer™ Antibody Discovery Platform. This synergy overcomes critical bottlenecks, accelerating the discovery of potentially more effective therapeutics.
We’re making this approach applicable to a wide range of challenging membrane protein targets. Read the full interview to learn more about how we are accelerating antibody discovery: https://drug-dev.com/executive-interview-salipro-biotech-bio-rad-laboratories-a-powerful-solution-for-antibody-discovery-against-challenging-transmembrane-targets/